Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,014 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease.
Saraf SL, Oh AL, Patel PR, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Jain S, Peace D, Quigley JG, Khan I, Molokie RE, Mahmud N, Gordeuk VR, Rondelli D. Saraf SL, et al. Among authors: khan i. Biol Blood Marrow Transplant. 2018 Aug;24(8):1759-1765. doi: 10.1016/j.bbmt.2018.03.031. Epub 2018 Apr 12. Biol Blood Marrow Transplant. 2018. PMID: 29656137 Free PMC article.
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study.
Patel P, Aydogan B, Koshy M, Mahmud D, Oh A, Saraf SL, Quigley JG, Khan I, Sweiss K, Mahmud N, Peace DJ, DeMasi V, Awan AM, Weichselbaum RR, Rondelli D. Patel P, et al. Among authors: khan i. Biol Blood Marrow Transplant. 2014 Dec;20(12):2034-41. doi: 10.1016/j.bbmt.2014.09.005. Epub 2014 Sep 16. Biol Blood Marrow Transplant. 2014. PMID: 25234438 Free article. Clinical Trial.
Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
Saraf SL, Oh AL, Patel PR, Jalundhwala Y, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Hassan J, Peace D, Quigley JG, Khan I, Molokie RE, Hsu LL, Mahmud N, Levinson DJ, Pickard AS, Garcia JG, Gordeuk VR, Rondelli D. Saraf SL, et al. Among authors: khan i. Biol Blood Marrow Transplant. 2016 Mar;22(3):441-8. doi: 10.1016/j.bbmt.2015.08.036. Epub 2015 Sep 5. Biol Blood Marrow Transplant. 2016. PMID: 26348889 Free article. Clinical Trial.
Nuclear FOXM1 drives chemoresistance in AML.
Khan I, Halasi M, Zia MF, Gann P, Gaitonde S, Mahmud N, Gartel AL. Khan I, et al. Leukemia. 2017 Jan;31(1):251-255. doi: 10.1038/leu.2016.270. Epub 2016 Oct 3. Leukemia. 2017. PMID: 27694928 No abstract available.
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.
Patel P, Oh AL, Koshy M, Sweiss K, Saraf SL, Quigley JG, Khan I, Mahmud N, Hacker E, Ozer H, Peace DJ, Weichselbaum RR, Aydogan B, Rondelli D. Patel P, et al. Among authors: khan i. Leuk Lymphoma. 2018 Jul;59(7):1666-1671. doi: 10.1080/10428194.2017.1390231. Epub 2017 Oct 25. Leuk Lymphoma. 2018. PMID: 29065747 Clinical Trial.
A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant.
Sweiss K, Anderson J, Wirth S, Oh A, Quigley JG, Khan I, Saraf S, Mactal-Haaf C, Rondelli D, Patel P. Sweiss K, et al. Among authors: khan i. Bone Marrow Transplant. 2018 Mar;53(3):300-306. doi: 10.1038/s41409-017-0024-1. Epub 2017 Dec 21. Bone Marrow Transplant. 2018. PMID: 29269796 Clinical Trial.
FOXM1 contributes to treatment failure in acute myeloid leukemia.
Khan I, Halasi M, Patel A, Schultz R, Kalakota N, Chen YH, Aardsma N, Liu L, Crispino JD, Mahmud N, Frankfurt O, Gartel AL. Khan I, et al. JCI Insight. 2018 Aug 9;3(15):e121583. doi: 10.1172/jci.insight.121583. eCollection 2018 Aug 9. JCI Insight. 2018. PMID: 30089730 Free PMC article.
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. Christian S, et al. Among authors: khan i. Am J Hematol. 2020 Aug;95(8):937-943. doi: 10.1002/ajh.25838. Epub 2020 May 8. Am J Hematol. 2020. PMID: 32311140 Free PMC article.
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
Abraham IE, Rauscher GH, Patel AA, Pearse WB, Rajakumar P, Burkart M, Aleem A, Dave A, Bharadwaj S, Paydary K, Acevedo-Mendez M, Goparaju K, Gomez R, Carlson K, Tsai SB, Quigley JG, Galvin JP, Zia M, Larson ML, Berg S, Stock W, Altman JK, Khan I. Abraham IE, et al. Among authors: khan i. Blood. 2022 Apr 7;139(14):2212-2226. doi: 10.1182/blood.2021012830. Blood. 2022. PMID: 35061876 Free PMC article.
6,014 results